Provided by Tiger Trade Technology Pte. Ltd.

INNOVENT BIO

98.050
+2.1502.24%
Volume:16.81M
Turnover:1.64B
Market Cap:171.10B
PE:208.62
High:99.350
Open:95.150
Low:94.800
Close:95.900
52wk High:112.700
52wk Low:69.550
Shares:1.75B
HK Float Shares:1.75B
Volume Ratio:1.98
T/O Rate:0.96%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.470
ROE:7.01%
ROA:2.23%
PB:7.06
PE(LYR):208.62
PS:9.32

Loading ...

INNOVENT BIO Grants 5,000 Share Options and 105,200 Restricted Shares

Stock News
·
Jun 15

Innovent grants 105,200 restricted shares under 2024 share plan

Reuters
·
Jun 15

Movement Alert|Innovent Biologics Rises 3.01% in Regular Trading, First Domestic PCSK9 Inhibitor Approval and ADA Data Catalyze Rebound

Market Focus
·
Jun 15

Innovent Biologics (SEHK:1801) Stock Valuation After Key Obesity Data And Priority Review Cancer Milestone

Simply Wall St.
·
Jun 14

Movement Alert|Innovent Biologics Rises 3.22% in Regular Trading, Technical Rebound After Multi-Day Decline as Biotech Sector Recovers

Market Focus
·
Jun 12

How Investors May Respond To Innovent Biologics (SEHK:1801) Advancing Oral And Extended-Interval GLP-1 Candidates

Simply Wall St.
·
Jun 11

Movement Alert|Innovent Biologics Falls 3.03% in Regular Trading, Pfizer Partnership Regulatory Uncertainty and Sector-Wide Selling Pressure Weigh on Stock

Market Focus
·
Jun 11

BREAKINGVIEWS-Pentagon casts dark cloud over China biotech

Reuters
·
Jun 09

Movement Alert|Innovent Biologics Falls 3.07% in Regular Trading, Pfizer Partnership Regulatory Uncertainty and Biotech Sector Selling Pressure Weigh on Shares

Market Focus
·
Jun 09

2026 Ada | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline

THOMSON REUTERS
·
Jun 08

Innovative Drug Stocks Under Broad Selling Pressure as Liquidity Tightening Weighs on Valuations; Analysts View BINSA Bill Impact as Sentiment-Driven

Stock News
·
Jun 08

Domestic Innovative Drugs Initiate Paradigm Shift in First-Line NSCLC Treatment, Says Orient Securities

Stock News
·
Jun 08

Movement Alert|Innovent Biologics Falls 3.59% in Regular Trading, Pfizer Deal Regulatory Approval Uncertainty Continues to Weigh on Stock

Market Focus
·
Jun 08

BUZZ-Innovent climbs most in a week on new drug application for gastric cancer

Reuters
·
Jun 05

Movement Alert|Innovent Biologics Rises 3.01% in Regular Trading, Global First CLDN18.2 ADC Drug Application Accepted for Gastric Cancer

Market Focus
·
Jun 05

Innovent Biologics Adds 10,000 Shares from Option Exercise; Issued Share Capital Reaches 1.74 Billion

Bulletin Express
·
Jun 04

Innovent Biologics' Application for Gastric Cancer Drug Accepted in China

MT Newswires Live
·
Jun 04

INNOVENT BIO Receives NMPA Priority Review for World’s First CLDN18.2 ADC Following Phase 3 Success

Bulletin Express
·
Jun 04

Innovent Biologics Announces NMPA Acceptance of New Drug Application for IBI343 in Advanced Gastric Cancer

Stock News
·
Jun 04

World's First Cldn18.2 ADC for Regulatory Review: Innovent Biologics Announces Ibi343 (Arcotatug Tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and Nda Accepted by China Nmpa

THOMSON REUTERS
·
Jun 04